With the addition of these CLAs, the companies are now working together to develop multiple biosimilar products in cancer and inflammatory diseases.
The companies announced the signing of the most recent previous CLAs in December 2017.
Selexis' proprietary SUREtechnology Platform facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein, including biosimilars, and provides seamless integration of the biologics development continuum, spanning discovery to commercialization.
Utilising the SUREtechnology Platform, Selexis has successfully generated numerous biosimilars, including marketed products, that have glycan profiles matching originator products.
The Selexis SURE CHO-M Cell Line is a proprietary high-performance mammalian cell line that is derived from CHO-K1 cells and used for the production of therapeutic recombinant proteins and monoclonal antibodies.
The growth and production properties of the Selexis SURE CHO-M Cell Line are well defined, and the feed strategy has been optimized, allowing for faster and more efficient scale-up to bioreactors.
Therapeutics that are generated using Selexis SURE CHO-M cells are in both clinical trials and marketed products.
Selexis in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialise innovative medicines and vaccines.
Its global partners are utilising Selexis technologies to advance more than 110 drug products in clinical development and the manufacture of four commercial products.
In June 2017, Selexis became part of the JSR Life Sciences group. JSR's CDMO service offering leverages the full capabilities of Selexis' proprietary SUREtechnology Platform to offer an end-to-end solution to industry.
Turgut Group, with over 50 years' experience, has recently incorporated its pharmaceutical activities under the roof of Turgut Pharmaceuticals, with a focus on biotechnology.
With its global collaborations, a fully integrated monoclonal antibody development platform and global standard GMP biotechnology manufacturing facility, Turgut Pharmaceuticals is a leading biotech company in Turkey with the vision to develop high-quality biosimilars that meet the strict regulatory requirements of highly regulated markets such as Europe and the United States.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine